抗アレルギー剤TA-5707の経口1回投与でのHouse Dust抗原による皮内反応および鼻誘発反応に及ぼす臨床薬理学的検討

抄録

The clinical effect of a new orally active anti-allergic agent, coded TA-5707 and chemically designed as 6-methyl-N-(1H-tetrazol-5-y1)-2-pyridine carboxamide sodium salt, was investigated in 12 male patients with allergic rhinitis. The drug was given orally in a single dose of 100mg. The skin and nasal porvocation tests were carried out with house dust.
The results were as follows:
1) Intracutaneous reaction at the threshold concentration was inhibited in 10 out of the 12 patients (83.3%). The inhibitory effect was stronger after 2 hr of administration than after 1hr of administration.
2) In the nasal provocation test conducted in 2 patients, nasal symptoms and nasal mucosal findings were evidently improved in both patients 1 hr after administra tion. At 2 hr the nasal provocation reaction was completely inhibited in one patient and remarkably suppressed in the other patient.
3) Neither subjective nor objective adverse reactions attributable to TA-5707 were observed in any patients.